Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Strategies to enhance response to poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)–proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Transl Med
Autores principales: Yang, Lu, Zhang, Youyou, Shan, Weiwei, Hu, Zhongyi, Yuan, Jiao, Pi, Jingjiang, Wang, Yueying, Fan, Lingling, Tang, Zhaoqing, Li, Chunsheng, Hu, Xiaowen, Tanyi, Janos L., Fan, Yi, Huang, Qihong, Montone, Kathleen, Dang, Chi V., Zhang, Lin
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705017/
https://ncbi.nlm.nih.gov/pubmed/28747513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal1645
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares